NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the 2017 Marcum Microcap Conference, taking place June 15-16 at the Grand Hyatt New York Hotel.
|Ohr Pharmaceutical Presentation Details|
|Date:||Thursday, June 15|
|Time:||2:30pm Eastern Time|
|Location:||Winter Garden, Conference Level|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company’s lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
CONTACT: Contact: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 [email protected] LifeSci Advisors, LLC Michael Wood 646-597-6983 [email protected]